212 related articles for article (PubMed ID: 23544841)
1. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases.
Liu TW; Macdonald TD; Jin CS; Gold JM; Bristow RG; Wilson BC; Zheng G
ACS Nano; 2013 May; 7(5):4221-32. PubMed ID: 23544841
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Imaging prostate cancer lymph node metastases with a multimodality contrast agent.
Hall MA; Kwon S; Robinson H; Lachance PA; Azhdarinia A; Ranganathan R; Price RE; Chan W; Sevick-Muraca EM
Prostate; 2012 Feb; 72(2):129-46. PubMed ID: 21538422
[TBL] [Abstract][Full Text] [Related]
5. 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.
Giesel FL; Kesch C; Yun M; Cardinale J; Haberkorn U; Kopka K; Kratochwil C; Hadaschik BA
Clin Genitourin Cancer; 2017 Jun; 15(3):e497-e499. PubMed ID: 28131751
[No Abstract] [Full Text] [Related]
6. Intrinsically copper-64-labeled organic nanoparticles as radiotracers.
Liu TW; MacDonald TD; Shi J; Wilson BC; Zheng G
Angew Chem Int Ed Engl; 2012 Dec; 51(52):13128-31. PubMed ID: 23154923
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
8. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
[TBL] [Abstract][Full Text] [Related]
9. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.
Schwarzenböck SM; Kurth J; Gocke Ch; Kuhnt T; Hildebrandt G; Krause BJ
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S28-35. PubMed ID: 23576101
[TBL] [Abstract][Full Text] [Related]
10. Tuning Pharmacokinetics to Improve Tumor Accumulation of a Prostate-Specific Membrane Antigen-Targeted Phototheranostic Agent.
Harmatys KM; Overchuk M; Chen J; Ding L; Chen Y; Pomper MG; Zheng G
Bioconjug Chem; 2018 Nov; 29(11):3746-3756. PubMed ID: 30350576
[TBL] [Abstract][Full Text] [Related]
11. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
12. A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection.
Hao G; Zhou J; Guo Y; Long MA; Anthony T; Stanfield J; Hsieh JT; Sun X
Amino Acids; 2011 Nov; 41(5):1093-101. PubMed ID: 20221650
[TBL] [Abstract][Full Text] [Related]
13. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
14. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
[TBL] [Abstract][Full Text] [Related]
16. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
17. Advancement of MR and PET/MR in Prostate Cancer.
Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
[TBL] [Abstract][Full Text] [Related]
18. Choline PET/CT for imaging prostate cancer: an update.
Kitajima K; Murphy RC; Nathan MA
Ann Nucl Med; 2013 Aug; 27(7):581-91. PubMed ID: 23632880
[TBL] [Abstract][Full Text] [Related]
19. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
20. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
